Green Tea Extract on Soluble RAGE in Patients With Diabetic Nephropathy
Status:
Unknown status
Trial end date:
2019-06-20
Target enrollment:
Participant gender:
Summary
Diabetic nephropathy is one of the most feared complications of Diabetes Mellitus type 2,
characterized mainly by the decrease in the glomerular filtration rate and an increase in
protein secretion by the kidney, that results in proteinuria. This has led to the development
of intensive treatment regimens for patients with diabetes and preventive measures since once
the complications have already presented the improvement of glycemic control alone may not be
enough, to prevent the progression of pathological processes. Currently, interventions to
delay the progression of kidney damage, include changes in lifestyle, nutritional advice and
regular exercise, achieve optimal levels in glycemic control and use of pharmacological
therapies with nephroprotector, angiotensin II receptor blocker (ARBs) and
angiotensin-converting enzyme inhibitors (ACEIs). The most important biochemical mechanism
proposed for this progression is the excessive binding of glucose to proteins, better
described as the final products of advanced glycosylation (AGEs); the interaction of AGEs
with its receptor (RAGE), participates in the metabolic and biochemical pathways in
intracellular signaling, either by favoring or aggravating cell nephron damage. Recently,
numerous RAGE isoforms have been described as: soluble RAGE, which are devoid of cytoplasmic
domains, which bind to ligands that include AGEs and can antagonize intracellular signaling.
Therefore, the need to seek for alternative therapies like nutraceuticals is arising, mainly
due to its low toxicity and lower cost. Such is the case of green tea extract, which due to
its chemical composition, especially of flavonoids that generate antioxidant and
anti-inflammatory effects, In vivo and in clinical trials have shown that it could impact the
progression of the diabetic neuropathy , through the modulation of the biological process,
including molecular and biochemical pathways such as release of soluble RAGE.
Phase:
Phase 2
Details
Lead Sponsor:
Centro Universitario de Ciencias de la Salud, Mexico